Methods and systems are disclosed relating to a lens system that allows for simultaneous focus of near and far-away images with one pair of glasses, heads-up-displays (HUDs), and the like, without the need to move the user's eyes. This lens system may be used in a HUD application, for example, where the user may focus on a display lens that may be approximately one inch from the eye to view computer-generated information such as altitude, temperature, directions, and the like, and simultaneously view the individual's surroundings. The lens system may include a liquid lens that when modulated may vary from a near-focus state to a far-focus state rapidly by using an electrowetting or piezoelectric hydraulic actuator. This variable rate lens may be multiplexed at a rate that allows both near and far-away images to appear in focus simultaneously through the advantageous use of a user's persistence of vision.

Methods and systems are disclosed relating to a lens system that allows for simultaneous focus of near and far-away images with one pair of glasses, heads-up-displays (HUDs), and the like, without the need to move the user's eyes. This lens system may be used in a HUD application, for example, where the user may focus on a display lens that may be approximately one inch from the eye to view computer-generated information such as altitude, temperature, directions, and the like, and simultaneously view the individual's surroundings. The lens system may include a liquid lens that when modulated may vary from a near-focus state to a far-focus state rapidly by using an electrowetting or piezoelectric hydraulic actuator. This variable rate lens may be multiplexed at a rate that allows both near and far-away images to appear in focus simultaneously through the advantageous use of a user's persistence of vision.

Provided are novel carbonohydrazonoyl dicyanide compounds including two or more aryl or heteroaryl groups connected via a linker and uses thereof.

A main object of the present invention is to provide a novel crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}acetic acid (hereinafter referred to as “Compound B”). A form-I crystal of Compound B, which shows peaks at diffraction angles (2θ) of 6.4°, 8.1°, 9.5°, 10.9°, 13.2°, 15.7°, 17.0°, 19.5°, 20.3°, 21.0°, and 22.8° in a powder X-ray diffraction spectrum obtained using a Cu-Kα radiation (λ=1.54 Å). A form-II crystal of Compound B, which shows peaks at diffraction angles (2θ) of 9.6°, 11.4°, 11.7°, 16.3°, 17.5°, 18.5°, 18.7°, 19.9°, 20.1°, 21.0°, and 24.6° in a powder X-ray diffraction spectrum obtained using a Cu-Kα radiation (λ=1.54 Å).

A main object of the present invention is to provide a novel crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}acetic acid (hereinafter referred to as “Compound B”). A form-I crystal of Compound B, which shows peaks at diffraction angles (2θ) of 6.4°, 8.1°, 9.5°, 10.9°, 13.2°, 15.7°, 17.0°, 19.5°, 20.3°, 21.0°, and 22.8° in a powder X-ray diffraction spectrum obtained using a Cu-Kα radiation (λ=1.54 Å). A form-II crystal of Compound B, which shows peaks at diffraction angles (2θ) of 9.6°, 11.4°, 11.7°, 16.3°, 17.5°, 18.5°, 18.7°, 19.9°, 20.1°, 21.0°, and 24.6° in a powder X-ray diffraction spectrum obtained using a Cu-Kα radiation (λ=1.54 Å).

Disclosed herein are heterocyclic compounds that inhibit the activity of FLT3. Also described are specific covalent inhibitors of FLT3. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the FLT3 inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of proliferative diseases or conditions, including hematological malignancies and other diseases or conditions dependent on FLT3 activity.

Disclosed herein are heterocyclic compounds that inhibit the activity of FLT3. Also described are specific covalent inhibitors of FLT3. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the FLT3 inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of proliferative diseases or conditions, including hematological malignancies and other diseases or conditions dependent on FLT3 activity.

A method for preparing an L-erythrobiopterin compound is provided. The L-erythrobiopterin compound has a structure represented by formula (I), and is mainly prepared from a compound having a structure represented by formula (II) or (III) through dihydroxylation. The preparation method of the L-erythrobiopterin compound is high in production efficiency, low in cost, environmentally friendly, and suitable for industrial production.

##STR00001##

The present invention relates to compounds of formula I: ##STR00001## in which m, Y.sub.1, Y.sub.2, Y.sub.3, R.sub.1, R.sub.2a, R.sub.2b, R.sub.3a, R.sub.3b, R.sub.4a, R.sub.4b, R.sub.5a and R.sub.5b are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.

The present invention relates to compounds of formula I: ##STR00001## in which m, Y.sub.1, Y.sub.2, Y.sub.3, R.sub.1, R.sub.2a, R.sub.2b, R.sub.3a, R.sub.3b, R.sub.4a, R.sub.4b, R.sub.5a and R.sub.5b are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.